期刊文献+

吸入一氧化氮治疗先天性心脏病术后肺动脉高压的疗效观察

The application of inhaled nitric oxide in management of postoperative pulmonary hypertension
原文传递
导出
摘要 目的 探讨吸入一氧化氮(NO)治疗先天性心脏病术后肺动脉高压患儿的疗效.方法 选择32例先天性心脏病术后传统治疗无效的、难治的、反应性肺动脉高压或肺动脉高压危象患儿,吸入NO(10~25)×10-6,定时记录各项血流动力学和呼吸功能指标,定期监测二氧化氮、高铁血红蛋白含量.结果 吸入NO后,平均肺动脉压(mPAP)从(38.0±3.2)mm Hg(1 mm Hg=0.133 kPa)降至(28.0±2.1)mm Hg,肺血管阻力从(62.2±6.7)kPa/(L·S)降至(49.9±5.6)kPa/(L·S),氧合指数从(67.0±30.1)mm Hg升至(92.6±25.0)mm Hg,动脉血氧饱和度从0.78±0.14升至0.84±0.09,差异均有非常显著性(P<0.01).吸入NO期间,二氧化氮和高铁血红蛋白含量均在安全范围.结论 NO可以明显降低先天性心脏病术后肺动脉压力和肺血管阻力,是一种安全且理想的肺血管扩张剂. Objective To evaluate the effects of inhaled nitric oxide (iNO) in management of postoperative pulmonary hypertension in the patients with congenital heart disease. Methods Thirty-two children with refractory pulmonary hypertension or pulmonary hypertensive crisis after open heart operations for congenital heart disease were treated with iNO. The changes of hemodynamics were observed. Results In iNO therapy group,the mean pulmonary artery pressure(mPAP) decreased from (38.0 ±3.2) mm Hg to (28.0 ±2.1) mm Hg,pulmonary vascular resistance (PVR) decreased from (62.2 ±6.7) kPa/(L·S) to (49.9 ±5.6) kPa/(L·S) ,PaO2/FiO2increased from (67.0 ±30. 1 ) mm Hg to (92. 6 ±25.0) mm Hg,and arterial oxygen saturation increased from 0. 78 ±0. 14 to 0. 84 ±0. 09 respectively. No toxic side effect was observed.Conclusion iNO is effective, safe to reduce pulmonary hypertension. It may play an important role in the treatment of postoperative pulmonary hypertension or pulmonary hypertensive crisis in the patients with congenital heart disease.
出处 《中国小儿急救医学》 CAS 2010年第4期336-337,共2页 Chinese Pediatric Emergency Medicine
关键词 先天性心脏病 一氧化氮 肺动脉高压 Congenital heart disease Nitric oxide Pulmonary hypertension
  • 相关文献

参考文献7

  • 1Beyens T,Biarent D,Bouton JM,et al.Cardiac surgery with extracorporeal circulation in 23 infants weighting 2500g or less:short and intermediate term outcome.Eur J Cardiothorac Surg,1998,14(2):165-172.
  • 2Adiatia I,Wessel DL.Diagnostic and therapeutic uses of inhaled nitric oxide in congenital heart disease.In:Zapple WM,Bloch KD.Nitric oxide and the lung.New York:.Marcel Dekker Inc,1997:365-392.
  • 3Steudel W,Hurford WE,Zapol WM.Inhaled nitric oxide:basic biology and clinical applications.Anesthesiology,1999,91 (4):1090-1121.
  • 4Zobel G,Gamillscheg A,Schwinger W,et al.Inhaled nitric oxide in infants and children after open heart surgery.J Cardiovasc Surg,1998,39(1):79-78.
  • 5Miller OI,Celemajer DS,Deanfield JE,et al.Very-low-dose inhaled nitric oxide:a selective pulmonary vasodilator after operations for congenital heart disease.J Thorac Cardiovasc Surg,1994,108(2):487-494.
  • 6Thelitz S,Oishi P,Sanchez LS,et al.Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs.Pediatr Crit Care Med,2004,5(3):234-239.
  • 7Foubert L,Fleming B,Latimer R,et al.Safety guidelines for the use of nitric oxide.Lancet,1992,339(8809):1615-1616.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部